Munich, Germany, September 11, 2025 / — As a leading specialist in the formulation and process development of biologics and complex small molecules—particularly antibody-drug conjugates (ADCs) and virus-based therapeutics—the company ProJect Pharmaceutics views this collaboration as a significant step in accelerating its expansion. Founders Dr. Andreas Schütz and Mr. Klaus Hellerbrand will remain substantial co-investors and continue to serve as managing directors.
Renowned for its deep scientific expertise and proprietary know-how in pioneering biologic therapeutics such as ADCs, ProJect Pharmaceutics has a proven track record of overcoming critical challenges in formulation and lyophilization process development using cutting-edge technologies. Long-standing partnerships with global biopharma and innovative biotechnology companies underscore the company’s unique position in the biopharma services landscape.
Well positioned for substantial growth opportunities, ProJect Pharmaceutics aims to expand its international customer base, leverage its expertise to broaden service offerings into adjacent areas, and pursue external growth opportunities. The company’s overarching goal remains to strengthen its leadership as a specialized innovation partner in biologics formulation and development.
The decision to partner with Afinum reflects ProJect Pharmaceutics’s commitment to preserving the entrepreneurial culture and scientific excellence that have defined the company since its founding in 2010 in Martinsried near Munich, Germany. Afinum’s experience in the healthcare sector and its history of successful investments in founder-led companies provide a strong foundation for executing an ambitious growth strategy. Future initiatives will focus on expanding ProJect Pharmaceutics’ global commercial footprint, diversifying its offerings, and investing in organizational development through targeted acquisitions.
This new chapter is expected to further reinforce ProJect Pharmaceutics’ position in the biologics market and drive innovation through strategic collaboration.
About ProJect Pharmaceutics GmbH
ProJect Pharmaceutics is one of the leading European service providers offering tailored pharmaceutical formulations and lyophilization processes for therapeutic proteins, peptides and other therapeutic compounds.
About Afinum Management GmbH
Since its founding in 2000, Afinum has been one of the leading private equity firms for medium-sized companies in the German-speaking region. With offices in Munich, Frankfurt, and Zurich, Afinum combines deep market knowledge in the DACH region with an international investor perspective and specializes in succession and growth investments within four technology-driven future verticals. Afinum partners with successful entrepreneurs to develop uniquely positioned companies to their full potential based on a trustful partnership approach. Autonomy and preservation of corporate culture and identity are of unique importance. This transaction marks the eleventh platform investment of the Afinum 9 fund and the second thematic investment in the Biopharma Services sector.